Abstract. Cancer stem cells (CSCs) are a small population of undifferentiated cancer cells within tumors, which contribute to tumorigenicity and relapse. In the current study, CD133 (also termed prominin-1), a CSC marker, was investigated to determine its involvement in predicting carcinogenesis and prognosis in patients with non-small cell lung carcinoma (NSCLC). CD133-positive lung cancer cells were isolated to analyze self-renewal, differentiation and tumorigenic abilities in vitro and in vivo. Quantitative polymerase chain reaction was used to detect the expression of CD133 and three other CSC-associated markers, octamer-binding transcription factor 4 (OCT4A), Nanog homeobox (NANOG) and multidrug resistance protein 1 (MDR1), in primary NSCLC and adjacent non-cancer tissues. A series of statistical methods were used to analyze the correlation between mRNA expression levels, clinicopathological features and patient survival. The results showed that CD133-positive NSCLC cells demonstrated clonogenic, tumorigenic and drug-resistance properties compared with their CD133-negative counterparts or parental cells. In addition, compared with the adjacent normal lung tissue, the levels of CSC-associated biomarkers CD133, OCT4A, NANOG and MDR1 were significantly increased in NSCLC tissue. Elevated expression of CD133 was associated with stage, tumor size and differentiation of NSCLC; however, the cox hazard regression analysis showed no significant association between CD133 expression and overall patient survival. The present study supports the hypothesis that the stem cell population can be enriched in cells expressing the CD133 cell surface marker and that highly expressed CD133 is involved in the occurrence of NSCLC. However, CD133 may not be considered as an independent factor in predicting the prognosis of patients with NSCLC. Further studies are required to investigate the association between CD133 expression and overall patient survival.
Introduction
Lung cancer is the most common cause of cancer-related mortality worldwide, and a poor five-year survival rate (15%) highlights the importance of gaining an improved understanding of this malignancy to improve prevention, diagnosis and treatment (1) . A previous study showed that tumor initiation and propagation is induced by a specific population of self-renewing tumor cells, termed cancer stem cells (CSCs) or tumor propagating cells (2) . Previous studies have indicated that similar to a number of solid tumors, human lung cancers, particularly non-small cell lung carcinoma (NSCLC), harbor CSC populations (3) (4) (5) .
Certain molecules are being investigated as putative markers of CSCs in malignancies, including lung cancer (6) . CD133 (also termed prominin-1), a cell-surface glycoprotein comprising five transmembrane domains and two large glycosylated extracellular loops, has been previously used as a biomarker to separate cancer stem cells from a variety of solid human tumors, including brain (7), breast (8) , liver (9) , pancreas (10), colon (11) and lung (12,13) tumors. Although CD133 has been used to enrich lung cancer CSCs in several studies, the potential for the use of CD133 as a key marker remains unclear (14) (15) (16) . In addition, the use of CD133 as a prognostic marker in lung cancer has not yet been confirmed due to conflicting studies (17) (18) (19) (20) (21) (22) . To investigate these divergent observations, the involvement of CD133 was analyzed using NSCLC cells and clinical specimens to evaluate a possible correlation between CD133 expression and clinical-pathological variables in patients with NSCLC. To the best of our knowledge, this was the first study to investigate NSCLC tumor and non-tumor tissue, with respect to CSC-marker expression profiles and their relevance to the clinicopathological parameters of lung cancer. The current results demonstrated that elevated expression of CD133 was associated with early clinical stages, larger tumor size and poor differentiation of NSCLC.
Materials and methods

Cell lines and isolation of CD133-positive cells. NSCLC cells, A549, H1299
, SPC-A1, SK-MES-1 and a human bronchial epithelial cell line (HBE), were cultured separately in RPMI-1640 medium (Gibco, Invitrogen Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS), 100 IU/ml penicillin and 100 mg/ml streptomycin in a 5% CO 2 humidified atmosphere at 37˚C. For isolation of CD133-positive cells, the parental H1299 cells were labeled with 1 ml CD133 per liter micromagnetic beads per million cells, using a CD133 cell isolation kit (CD133 MicroBead kit; Miltenyi Biotec, Auburn, CA, USA). The isolated CD133-positive cells were cultured in medium consisting of serum-free Dulbecco's modified Eagle's medium (DMEM)/F-12 medium (Gibco, Invitrogen Life Technologies) supplemented with 20 ng/ml human epidermal growth factor (EGF) (PeproTech, Rocky Hill, NJ, USA), 10 ng/ml human basic fibroblast growth factor (bFGF; PeproTech) and 2% B-27 serum-free supplements (Invitrogen Life Technologies). The medium was replaced or supplemented with fresh growth factors twice weekly until floating aggregates formed.
To determine the percentage of single cells capable of regenerating novel spheres, cells were plated at a density of 1,000 cells/ml in ultralow-attachment 6-well plates (Corning Life Sciences, Union City, CA, USA) to obtain the novel spheres. The total number of tumor spheres was counted following 10 days of culture. Efficiency of sphere formation was calculated by the following equation: (Total number of spheres formed / total number of living cells seeded) x 100.
Patients and tissue samples. NSCLC and matched adjacent normal biopsies were obtained from 30 patients (see supplementary Table Ⅰ) undergoing pulmonary resection at the Zhoushan Hospital of Zhejiang province (Zhoushan, Zhejiang, China) between January 2009 and May 2010. All samples were collected with informed consent obtained at an internal review. The ethics board committees of the Zhoushan Hospital of Zhejiang province approved the current study. Patients recruited into the study had not undergone chemotherapy or radiotherapy prior to surgery. Surgical specimens of the resected tumors were collected following the confirmation of diagnosis by pathological examination. Tumor sections and matched adjacent noncancerous tissues, were placed in separated cryovials and snap-frozen in liquid nitrogen until analysis. All cases were reviewed by two pathologists and diagnosis was confirmed according to criteria previously established by the National Comprehensive Cancer Network (23 ) were plated in 96-well plates. Cisplatin and paclitaxel (Sigma-Aldrich, St. Louis, MO, USA) were added to the culture medium at a final concentration of 25 µg/ml and 20 µM, respectively, for 24 h. Subsequently, cell viability was analyzed by an MTT assay.
In vivo analysis of tumor growth. Female nude mice (strain, BALB/c; age, 4 weeks) were obtained from the Shanghai Laboratory Animal Center (Shanghai, China). Specific numbers of parental and sorted cells (10 3 , 10 4 or 10 6 cells) were subcutaneously injected into the flank of the nude mice. Tumor growth was monitored and volume was measured weekly using a caliper (volume = width x length 2 x π/6) for a maximum of 8 weeks. Subsequently, mice were euthanized by cervical vertebra dislocation and the tumors were collected, fixed in formalin and embedded in paraffin for further use.
Statistical analysis. Statistical analyses were performed with the GraphPad Prism 5.0 statistical software (GraphPad Software, Inc., La Jolla, CA, USA). The paired t-test, unpaired t-test and Mann-Whitney U test were used to analyze the correlation between mRNA expression levels and the clinicopathological features. The paired sample t-test was used to compare the differences of mRNA expression between lung tumors and the surrounding normal tissue. Survival analysis was estimated by the Kaplan-Meier method and the log-rank test was used to compare the survival between groups. The Cox proportional hazard regression model was used to analyze the risk factors for lung cancer. P<0.05 was considered to indicate a statistically significant difference.
Results
Isolation and characterization of CD133-positive cells from lung cancer cell lines.
To investigate the involvement of CD133 in the link between CSCs and lung cancer biology, CD133-positive cells were isolated from lung cancer cell lines using the magnetic bead method to determine the expression levels of CD133. CD133 was shown to be highly expressed in, 95C, SPC-A1, A549 and H1299 NSCLC lines. The highest expression levels were observed in the H1299 cells (Fig. 1A) . Thus, H1299 cells were used for all subsequent experiments.
The isolated CD133-positive cells identified by flow cytometry formed floating sphere-like bodies in DMEM/ F-12 serum-free medium with bFGF and EGF. When CD133-positive cells were grown under adherent conditions in culture medium supplemented with 10% FBS, the cells acquired the typical morphological features of parental H1299 cells with the loss of CD133 expression (decrease in expression from 94.9 to 4.9%; Fig. 1B) . qPCR results demonstrated that the expression of stemness genes (OCT4A, SOX2 and NANOG) and drug resistant genes (MDR1 and ABCG2) in CD133-positive cells were higher compared with those in the CD133-negative cells (Fig. 1C) . The ability to form spheroid-like bodies was significantly higher in the CD133-positive cells compared with the parental or CD133-negative cells (P<0.05; Fig. 1D ). The multidrug chemotherapy resistant abilities of the CD133-positive cells and CD133-negative cells were then investigated. Compared with the CD133-negative and parental cells, CD133-positive cells sorted from H1299 cells were more resistant to cisplatin and paclitaxel (P<0.05; Fig. 1E ).
To analyze the tumorigenic potential of CD133-positive cells grown under sphere-forming conditions, during which this property of stem cells may be maintained, specific numbers of H1299 CD133-positive, CD133-negative and parental cells were subcutaneously implanted into the flanks of nude mice (BALB/c strain). As shown in Table Ⅱ , tumor growth was observed in all groups in which mice were inoculated with 10 3 -10 6 CD133-positive cells, whereas no tumor growth was observed following inoculation with 10 3 H1299 parental or CD133-negative cells ( Fig. 2A) . Tumor growth curves showed that tumors that had developed from the CD133-positive cells grew at a faster rate compared with those that had developed from the parental or CD133-negative cells (Fig. 2B ). These observations indicated that CD133-positive lung cancer cells may be used to enrich tumor-initiating cells under sphere-forming conditions.
Patient information. Tumor specimens from 30 patients (19 paired samples of lung adenocarcinomas and 11 paired samples of lung squamous-cell carcinomas) with previously untreated NSCLC were recruited into the current study. The patients consisted of 23 males and 7 females. The median age 
Cancer stem cell-associated gene expression in lung tissue.
A primary aim of the current study was to determine whether ) were plated in a 96-well plate and treated with the indicated concentrations of cisplatin and paclitaxel for 24 h. The survival rate was determined by a cell counting kit-8 assay. Data are presented as the mean ± SD of three independent experiments. * P<0.05, vs. CD133-negative and H1299 parental cells. qPCR, quantitative polymerase chain reaction; Ct, cycle threshold; bFGF, basic fibroblast growth factor; EGF. epidermal growth factor; OCT4A, octamer-binding transcription factor 4; SOX2, sex determining region Y-box 2; NANOG, Nanog homeobox; MDR1, multidrug resistance protein 1; ABCG2, ATP-binding cassette subfamily G member 2; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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there was a difference in the frequency of CSC-associated gene expression between paired lung carcinoma and the corresponding noncancerous lung tissue. The results from the qPCR analysis showed that, compared with the adjacent normal lung tissues, the levels of CSC-associated biomarkers, such as OCT4A, CD133, NANOG and MDR1, were significantly increased in lung cancer tissues (P<0.05; Fig. 3 ). The mRNA levels of CD133 (Fig. 3A) and MDR1 (Fig. 3D) Fig. 3C and B) .
Correlation between the expression of cancer stem cell-associated genes and clinical-pathological features of NSCLC.
The correlation between the expression of CSC-associated genes 
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and clinicopathological features of NSCLC was investigated to gain an improved understanding of the potential involvement of these genes in NSCLC development and progression using the Mann-Whitney U test (Table Ⅲ) . No substantial correlation between the expression of NANOG or MDR1 and the tumor stage, nodal status, tumor size and histological type was observed, with the exception of tumor differentiation. However, overexpression of CD133 in lung tumors was observed to be markedly associated with clinical stage, tumor size and differentiation of NSCLC (P=0.0334, 0.0238 and 0.0376, respectively; Fig. 4A-C) . In addition, patients with squamous-cell lung carcinoma or a tumor ≥3 cm in diameter exhibited higher expression levels of CD133. Notably, overexpression of OCT4A in tumors was positively associated with a tumor stage I or II and moderate-well differentiated tumors (P=0.0417 and 0.0396, respectively; Fig. 4D and E) . In addition, patients with poor differentiation had higher levels of CD133 and OCT4A.
Correlation between cancer stem cell-associated gene expression and overall survival of NSCLC patients. The expression of CSC-associated genes and its correlation with overall survival of NSCLC patients was investigated (fold change >2 was considered as high expression). The results showed that higher levels of expression of CD133 in NSCLC was independently correlated with shorter overall survival (log-rank test: P= 0.0258, Fig. 5 ). However, no significant correlation between the expression of OCT4A and the overall survival was observed (log-rank test: P=0.1395). In addition, tumor size >3 cm was observed to be associated with decreased overall survival (log-rank test: P=0.015, data not shown). The Kaplan-Meier survival curve showed a trend for an improved outcome in patients with lower CD133 mRNA signals; however, the Cox hazard regression analysis indicated that CD133 was not considered to be an independent factor in predicting the prognosis of patients with NSCLC (hazard ratio: 0.179; 95% confidence interval: 0.010-3.205; P=0.243).
Discussion
Lung cancer is characterized by the difficulty surrounding early diagnosis, high rates of metastasis, recurrence and poor prognosis. Thus, investigating novel diagnostic strategies and novel prognostic markers is urgently required to improve the clinical outcome of this malignancy (1). Increased numbers of CD133-positive cancer stem cells have been observed in Table Ⅲ . Correlation between the expression of CSC-associated genes and the clinicopathological factors in patients with NSCLC.
Mean ± SEM P-value Mean ± SEM P-value Mean ± SEM P-value Mean ± SEM P-value NSCLC (13) . In the current study, isolated CD133-positive cells were shown to harbor stem cell-like characteristics, as they readily form anchorage-independent floating spheres, possess greater proliferative potential and exhibit enhanced tumor regenerating capacity compared with their CD133-negative counterparts. In addition, CD133-positive, but not CD133-negative or parental NSCLC cells formed tumors in the nude mice xenograft model. These results demonstrated the CSC status of CD133-positive cells in NSCLC.
The correlation of CSC-associated gene expression (CD133, OCT4A, NANOG and MDR1) in NSCLC samples, with patient characteristics, tumor pathology and overall survival was investigated. The current results indicated the presence of CSCs in NSCLC tissue, as self-renewal and multipotency are critical characteristics of CSCs (4) . Based on the present observations, the correlation between increased CD133 expression and early stage tumors, larger tumor size and poorly differentiated NSCLC tumors may be to be due to the self-renewal properties of aberrant CSCs. This implicated the importance of CD133-positive cells in the initiation of NSCLC. The reduced levels of CD133 in the later stages of NSCLC may be explained by the hypothesis that cells expressing CD133 undergo asymmetric division, generating a diverse phenotype and therefore resulting in reduced CD133 positivity. However, further studies are required to confirm this.
Previous studies have shown that the expression of CSC antigens was associated with a poor prognosis (20) (21) (22) 25, 26) . However, the current observations, which are consistent with the results of other studies (17) (18) (19) , demonstrated that while the expression of CD133 in the surgically resected specimens was involved in NSCLC carcinogenesis, CD133 alone may not be used as an independent biomarker in the prediction of the prognosis of NSCLC. The origin of these discrepancies remains unclear; however, specific NSCLC samples may be the reason for variability between the results. Notably, the present specimens were obtained from patients with all stages of NSCLC and contained various histological types (adenocarcinoma and squamous carcinoma).
Studies in human embryonic stem cells indicated that OCT4A and the homeobox protein NANOG were two key transcription factors that cooperatively maintained pluripotency (27, 28) . The present results indicated that OCT4A was significantly associated with the clinical stage and differentiation of NSCLC. Consistent with this, Chen et al (29) observed that knockdown of the OCT4A gene in CD133-positive stem-like lung cancer cells significantly diminished the Figure 5 . The Kaplan-Meier method and the log-rank test were used to compare the overall survival in high and low CD133 expression groups. Kaplan-Meier survival curves for NSCLC patients were plotted for expression, which was based on CD133 cut-off values. The P-value was calculated using the log-rank test between patients with high-and low-fold changes. The overall survival of patients with high vs. low expression levels of CD133 is shown. P<0.05, vs. the two groups. CD133, prominin-1; NSCLC, non-small cell lung carcinoma.
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ability of tumor invasion and colony formation, and increased apoptotic activities. The aforementioned observations indicate that the expression of OCT4A was involved in maintaining the stem cell-like properties of lung cancer cells. Whether the combination of the two CSC markers, OCT4 and CD133, may enhance the predictive validity of patient progression and survival remains to be elucidated.
In conclusion, the results of the present study show that CD133-positive NSCLC cells exhibit clonogenic, tumorigenic and drug-resistant properties. The elevated expression of CD133 was associated with early stage tumors, larger tumor size and poor differentiation of NSCLC, indicating that highly expressed CD133 is involved in the carcinogenesis of NSCLC. However, expression of CD133 in CSCs is not considered to be an independent factor in the prediction of the prognosis of patients with NSCLC. Further studies are required to determine the association between CD133 expression and overall survival in NSCLC patients, with or without other CSC-associated genes.
